IGF1R and cancer: As shown in Figure 3E, BMS-536924, an IGF-1R inhibitor, when added into the DORexo-treated BMSCs, could inhibit the promotion of cancer cell proliferation cocultured with the DORexo BMSCs (Figure 3E, P < 0.05).